GoodRx (GDRX) Q4 2024 earnings summary

Executive summary

• New CEO and CFO bring extensive pharmacy and healthcare experience, focusing on accelerating innovation and deepening industry partnerships.

• GoodRx operates a scaled digital healthcare platform focused on prescription savings, serving nearly 30 million consumers in 2024 and delivering approximately $17 billion in annual consumer savings.

• The company leverages a hybrid contracting model with PBMs and direct pharmacy contracts, expanding its reach and value proposition.

• Strategic priorities include expanding brand partnerships, enhancing pharmacy profitability, building prescriber channels, scaling pharma manufacturer solutions, and broadening integrated savings programs.

• GoodRx's solutions address rising healthcare costs, narrowing formularies, and increased uninsured or underinsured populations.

Financial highlights

• 2024 revenue reached $792.3 million, up 6% year-over-year, with Adjusted EBITDA of $260.2 million and a 32.8% margin.

• Net income was $16.4 million, reversing a net loss of $8.9 million in 2023; adjusted net income rose to $131.6 million.

• Operating cash flow was $183.9 million, with $448.3 million in cash on hand and $500 million in debt.

• Pharma manufacturer solutions revenue surged 26% to $107.2 million, reflecting expanded market penetration.

• Subscription revenue declined 8% to $86.5 million due to the sunset of a retailer-specific program.

Outlook and guidance

• 2025 revenue expected between $810–$840 million, representing 4% growth at midpoint.

• Adjusted EBITDA guidance for 2025 is $270–$286 million, about 7% growth at midpoint.

• Q1 2025 revenue expected at $201–$205 million, with Adjusted EBITDA margin stable at ~33%.

• U.S. prescription drug spend is projected to grow 5% annually, supporting continued market expansion.

• Management maintains a disciplined approach to guidance, balancing visibility and adaptability.